Molecular imaging plays a central role in the management of radiation oncology patients. Specific imaging uses, particularly to plan radiotherapy and assess its efficacy, require an additional level of reproducibility and image quality beyond what is required for diagnostic imaging. Specific requirements include proper patient preparation, adequate technologist training, careful imaging protocol design, reliable scanner technology, reproducible software algorithms, and reliable data analysis methods. As uncertainty in target definition is arguably the greatest challenge facing radiation oncology, the greatest impact that molecular imaging can have in radiation oncology may be in the reduction of inter-observer variability in target volume delineation, and in greater conformity between target volume boundaries and true tumor boundaries. Several automatic and semi-automatic contouring methods based on molecular imaging are available, but still need sufficient validation to be widely adopted.
Introduction
Molecular imaging plays a central role in the management of radiation oncology patients. While most of the uses and applications of molecular imaging in radiation oncology are not significantly different than in general oncology (e.g., diagnostic applications), there are some specific imaging requirements and uses which warrant separate discussion and review, particularly when used to plan radiotherapy and assess its efficacy (Figure 1 ).
Radiation therapy is a localized cancer treatment modality, and as such requires accurate spatial localization of the tumor. Spatial localization has traditionally relied on anatomical imaging such as CT and MRI, but added benefits of molecular imaging (e.g., increased sensitivity and specificity) make molecular imaging, and especially combined modalities, such as PET/CT, particularly appealing. However, accurate special localization increases complexity of the imaging procedure. For example, as patient (and tumor) position within the treatment system needs to be maintained during radiotherapy, the scanning position during molecular imaging procedures has to be similarly maintained. These extra requirements increase the complexity of the process, not only to molecular image acquisition, but also to image analysis. With the recent interest in biologically-conformal radiotherapy (dose painting), where one would potentially target spatially heterogeneous distribution of tumor resistance with variable levels of radiation dose, the requirements for molecular imaging quantification are further augmented.
2-deoxy-2-(
18 F)fluoro-D-glucose (FDG) PET/CT has been the main imaging modality of choice for treatment response assessment. However, due to radiation-induced inflammation, treatment response assessment time points need to be carefully selected. Since inflammatory processes initiated during radiation therapy can persist for months following the end of radiotherapy, both late (post-treatment) response assessment, and particularly early (during-treatment) response assessment based on FDG PET/CT requires complex interpretation.
Solid tumors that are commonly treated with radiotherapy or chemoradiotherapy show variable resistance to therapy, ranging from very sensitive tumors (e.g. lymphoma, seminoma) to highly resistant tumors (e.g. The purpose of this review is to provide comprehensive and contemporary overview of molecular imaging applications in radiation therapy, particularly for target definition and treatment response assessment.
Specific quantitative imaging requirements for use in radiation therapy, and potential confounding artifacts that limit image interpretation will be highlighted. Future perspectives for full exploration of molecular imaging, particularly for biologically conformal applications of radiotherapy, will be discussed.
by on October 13, 2017 . For personal use only. jnm.snmjournals.org Downloaded from CT. As such, molecular imaging acquisitions for radiation therapy treatment planning need to follow similar principles as recommended for planning CT (or simulation CT) acquisitions [6] .
The patient must be positioned and immobilized during image acquisition in the same manner as he or she will be for each fraction of therapy. As flat-top couches are used for radiation therapy delivery to ensure repeatable positioning, a flat-top table should be placed on top of the patient table. Any immobilization devices, padding, or bolus material should be in place during the scan. For nuclear medicine, placement of positioning equipment outside the transaxial imaging field-of-view but within the scanner bore should be avoided, as it can lead to attenuation artifacts [7] . Scanners with large bores are preferred to accommodate the extra equipment.
Positioning for functional MRI can be more challenging, depending on the tumor site [8] . For example, for head and neck cancer, personalized masks are often used to ensure reproducible positioning and immobilization, but these masks often do not fit inside standard head coils. Furthermore, MRI bores are often smaller than CT bores, potentially limiting the use of some positioning devices. In these cases, creative solutions may be necessary [9] . In addition to the internal positioning lasers included with imaging systems, it is preferable to have mobile external lasers for patient marking/tattooing and positioning, similar to those used during CT simulation. The lasers' positions should maintain a precise and known spatial relationship to the image center, so that patients can be marked in a way that will ensure repeatable positioning at subsequent treatment sessions. Quality assurance tests for external laser alignment accuracy have been described by The American Association of Physicists in Medicine (AAPM) Task Group 66 [6] .
For PET/CT imaging, there are different options for how the CT component of the PET/CT can be acquired. Attenuation and scatter correction for PET image reconstruction can typically be performed using either a low-dose CT or a high-quality diagnostic CT. The preferred option is to acquire a single high-quality CT scan together with the PET scan, which can then be used for treatment planning. In this case, no additional image registration is needed to align the PET image and planning CT. Treatment planning CTs, however, are sometimes acquired with intravenous contrast. Unless corrected for, contrast-enhanced CTs can cause the PET voxel values in regions of high contrast density to be increased when used for attenuation correction [10] . In these cases (or by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from when planning CTs have been acquired separately), an additional low-dose CT scan should be acquired together with the PET scan. This low-dose CT image can be used for attenuation and scatter correction, but is not suitable for treatment planning. If a contrast CT is to be acquired during the PET/CT exam, it should occur following both the attenuation CT and PET acquisitions. A promising alternative to PET/CT imaging, which will become more prevalent in the future, is PET/MRI imaging, in which pseudo CT images are created and used for PET attenuation correction [11] and potentially also for radiotherapy planning [12] . The challenge of pseudo CT generation is that the MRI intensity value of single voxel cannot be uniquely mapped into the γ-ray attenuation coefficient. While several methods to improve the accuracy of pseudo CT mapping (e.g., registered atlas CTs) have been developed [11] , these methods have yet to be thoroughly validated for use in radiation therapy treatment planning.
Registration
For cases when the planning CT is not already registered to the functional images, the two image coordinate systems need to be aligned. Rigid registration algorithms rotate and translate images so that two images have maximum spatial similarities in intensity values. Most modern image analysis software packages include methods for performing rigid registration. For PET, the CT from the PET/CT acquisition is typically registered to the planning CT, and the resulting spatial transformation is then applied to the respective PET image.
It should be noted that voxel sizes for PET images are larger than CT voxel sizes, and, depending on the software, may need to be up-sampled before PET can be used for target delineation. Unless nearest-neighbor resampling is used, this resampling step will alter the quantitative SUV values, therefore, quantitative image analysis for treatment response assessment should be performed prior to the PET image registration. For functional MRI, anatomical MRI sequences, such as volumetric T1-weighted imaging, should also be acquired during imaging so that MRI and CT images can be coregistered. Special software may be required to register anatomical MRI and CT images, as the imaging values for different tissues are inherently different between the two imaging modalities.
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In many cases, patient positioning will not be identical in the molecular images and in the planning CT image. This can make rigid registration difficult, and can occasionally cause algorithms to converge to strange solutions (results should always be checked). One option, if the software allows it, is to crop the template image, leaving only the regions of interest to be registered. Another option is to use deformable registration algorithms.
Like rigid registration, deformable registration algorithms maximize the similarities between two images, but allow for morphological changes beyond rotation and translation. These algorithms ultimately warp the template image to match the reference image. There are a number of deformable registration algorithms, each with different similarity measures or regularization constraints. The resulting solution will be different depending on the algorithm used, so an algorithm should not be arbitrarily chosen [13] . Quality assurance processes for image registration have been proposed [14] , and an upcoming report from Task Group 132 of the AAPM will further describe the proper use and quality assurance of image registration algorithms.
Motion
Patient motion during imaging causes the image to be blurred over the path of motion, elongating target volumes. Motion also affects image quantification, effectively reducing image intensity values [15] . Certain motion, such as breathing, cannot be avoided during treatment, and will affect imaging of the lungs, liver, esophagus, pancreas, breast, prostate, kidneys, and other organs. Lung motion amplitudes are case dependant, but usually range between 0 to 30 mm in the superior-inferior direction, with an average amplitude around 10 mm [16] .
The degree to which motion should be compensated for during imaging depends on the degree to which motion will be accounted for during treatment. In other words, motion management for imaging should be coupled to motion management strategies during radiation delivery. In the case of PET, the simplest strategy would be to apply no motion corrections to PET images, as both PET imaging and radiation therapy delivery encompass all phases of respiratory motion. Likewise, slow CT imaging can be used to create a phase-averaged by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from CT image [17] . Not accounting for motion during planning and radiation therapy delivery, however, can result in unnecessary dose to nearby healthy organs.
There are several methods to reduce or account for respiratory motion during imaging and radiation therapy delivery. A detailed description of these methods is beyond the scope of this review, but has been described elsewhere [16] . These methods include shallow or tidal breathing to limit motion amplitude, respiratory gating [16, 18] , and real-time tumor tracking [19] [20] . In any case, the type of image acquisition should be closely matched with the type of radiation treatment delivery (e.g., 4D PET/CT together with real-time radiation delivery tracking).
Uncertainties
Uncertainties in molecular imaging arise from technical factors (e.g., scanner calibration), physical factors (e.g., positron range), biological factors (e.g., patient metabolism), analytical factors (e.g., inconsistent image processing) [21] [22] , and statistical factors (e.g., image noise). Some of these uncertainties can be controlled or minimized through careful study design and quality assurance procedures (see Table 1 for examples specific to FDG PET). Understanding the limitations and uncertainties of molecular imaging is necessary to its proper implementation in radiation oncology.
For PET imaging, one of the limitations is its spatial resolution. There are many factors that affect PET spatial resolution, but in general, PET-avid lesions with diameters less than 5-10 mm are unlikely to be discernible from background in a typical clinical PET image [23] . Consequently, small lesions, some positive lymph nodes, sharp intra-tumor heterogeneities, and microscopic tumor extensions may not be resolved in a PET image. PET's limited spatial resolution has implications for its use in target volume delineation and treatment response assessment.
Uncertainties in molecular image quantification will propagate into uncertainties in treatment response assessment. Quantitative imaging for treatment response assessment requires proper calibration of the scanner by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from equipment (including the dose calibrator for nuclear medicine) at acceptance testing and during routine maintenance. A detailed quality assurance plan, including daily, quarterly, and annual calibrations, is necessary to ensure the reliability and consistency of the scanner equipment [24] [25] . For MRI imaging, quality assurance procedures that minimize geometric distortion caused by gradient field nonlinearity or static field inhomogeneity are especially important. Even with properly calibrated equipment, however, biological variability and statistical noise cause substantial uncertainties in molecular imaging. For example, test-retest studies with FDG PET imaging suggest that biological and statistical uncertainties contribute to an overall uncertainty (coefficient of variation) in maximum standardized uptake value (SUV max ) of about 10-15% [26] [27] . Even the position of a lesion relative to the detector array geometry can cause fluctuations in PET SUV for small lesions [28] .
There are also uncertainties on how to best extract meaningful quantitative imaging biomarkers from molecular images. In PET, the semi-quantitative SUV is easily calculated my normalizing the measured radioactivity concentration in an image voxel by the ratio of the patient's injected activity to their body weight --either the total body weight (SUV) or lean body mass (SUV lean ). Both the mean and maximum SUV of a regionof-interest are typically reported. However, depending on the application and radiotracer used, SUV may not represent a reliable measure of the biological process of interest, and can be very sensitive to the conditions of the acquisition, reconstruction, and analysis. In these cases, dynamic imaging with kinetic analysis may be necessary to understand the tracer kinetics and extract the most biologically-relevant parameters. Dynamic scans are much more challenging to perform and to analyze than static scans.
In MRI, similar challenges in image quantification exist. For example, it is becoming increasingly common for apparent diffusion coefficients (ADC) from diffusion-weighted (DW) MRI to be measured in clinical exams, but standardized protocols for acquisition and analysis of DW MRI images are lacking, especially across vendors [29] . This lack of standardization also applies to perfusion MRI, where kinetic parameters relating to blood flow are modeled and calculated. Standards for appropriate uses and analyses of quantitative imaging biomarkers, including proper characterization of their uncertainties, are being developed by the Quantitative Imaging Biomarkers Alliance (QIBA) [30] .
In PET imaging, quantitative PET image values are highly sensitive to the algorithm used to reconstruct the images [31] . With iterative reconstruction algorithms (which have become standard in clinical PET imaging) and a growing library of image correction methods (e.g., point spread function modeling), there are hundreds of possible combinations of reconstruction parameters. Furthermore, the optimal reconstruction method may depend on the region of interest (eg, chest versus brain). It is therefore incumbent on an institution's nuclear medicine physicians, physicist, and/or technologists to determine the reconstruction method that results in optimal image quality for a particular PET scanner. This generally involves scanning a PET image quality phantom, exploring several different reconstructions, and finding the parameter set that offer the best trade-off between spatial resolution and image noise. Furthermore, as different PET scanners can have substantial differences in image quality and quantitative accuracy, image reconstruction parameters can be tuned such the different PET scanners involved in a multi-center study produce comparable image quality. This process of scanner harmonization can improve the statistical power of multi-center clinical trials investigating imaging biomarkers [32] .
Overall, many uncertainties in molecular imaging and in its application to radiation oncology can be minimized by using a detailed and unambiguous protocol for acquisition and image analysis. One such protocol is the FDG PET imaging protocol developed by the Uniform Protocols for Imaging in Clinical Trials (UPICT) working group [33] . Strict adherence to protocols ensures that for baseline and for follow-up imaging, identical procedures will be followed for patient preparation, patient immobilization, radiotracer or contrast injection, acquisition settings, image reconstruction/corrections, image processing, and image analysis. Minimizing these quantitative imaging uncertainties will allow for more precise quantification of treatment response [34] .
Molecular imaging for target definition
Uncertainty in target definition is arguably the greatest challenge facing radiation oncology. Recent technological advances in radiation delivery and dosimetry allow for very precise and conformal delivery of dose to patients. Exactly where that dose should be delivered, on the other hand, is still not very clear. The impact that uncertainty in target volume delineation has on patient dosimetry is almost an order of magnitude greater than the impact of tumor motion [16, 35] . Perhaps the greatest impact that molecular imaging can have in radiation oncology is in the reduction of inter-observer variability in target volume delineation, and in greater conformity between target volume boundaries and true tumor boundaries. An upcoming report from Task Group 211 of the AAPM will further describe the proper use of FDG PET/CT for target definition.
Manual tumor segmentation
Currently, the most common method for molecular imaging-based gross tumor volume (GTV) delineation is manual segmentation. A prerequisite for all molecular imaging-based segmentation methods is an understanding of the normal biological processes that will be measured in the images, so that normal tissue is not mistaken as diseased tissue during segmentation. Potential sources of false-positives and false-negatives should be well-understood. For example, in the case of FDG PET, brown adipose tissue, granulous tissue, areas of inflammation, and muscle often have elevated levels of FDG uptake and can be mistaken as tumor [1, 36] . PET images should be interpreted by nuclear medicine physicians and MRI images by radiologists before being used for radiation therapy purposes so that, if necessary, previously-unknown lesions can be detected, and potential image artifacts can be identified.
Following image registration, the molecular and anatomical image should be fused in the visualization software [37] . All available information should be used for defining the target volume. Manual segmentation methods, however, are known to suffer from inter-and intra-observer variability in target volume delineation. To reduce this variability, it is recommended that institutions develop a strict delineation protocol, which describes by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from exactly how the tumor should be visualized (e.g., window level and color settings), and details any other parameters that can impact physician contouring [38] . Because of the significant inter-and intra-observer variability, manual segmentation is generally inferior to automatic and semi-automatic segmentation methods and as such is discouraged. However, it will take some time for the manual segmentation to be entirely substituted with automatic and semi-automatic segmentation tools, which still require more rigorous clinical validation (see next section).
If using DW-MRI for tumor segmentation, special attention should be paid to the potential for spatial distortions in the ADC maps. Studies have found that substantial geometrical distortions can occur in DW-MRI images, even on the order of centimeters [39] . Such distortions, both global and local, can also occur for other imaging sequences, including sequences used for perfusion MRI. If not accounted for, these distortions can substantially impact the accuracy of the target volume delineation.
Automatic and semi-automatic tumor segmentation
Computer algorithms that automate tumor volume segmentation based on molecular images can improve workflow and reduce physician variability in target definition. In PET, the most common method for automatic segmentation is thresholding based on SUV. There are different ways by which thresholding can be performed. A threshold based on the maximum SUV is the most commonly-used method, and usually the most simple. The threshold value for FDG PET is often set around 40% of SUV max , but varies from 20 % to 50%. Other types of thresholding include using a fixed SUV threshold (e.g., SUV ≥ 2.5 [40] ), using a background-subtracted threshold [41] , as well as others. A clear disadvantage of thresholding is the uncertainty regarding which threshold value is optimal, which can vary depending on the scanner hardware, reconstruction and acquisition parameters, presence of motion, tumor size, and patient biology [42] . Furthermore, thresholding cannot distinguish normal uptake from disease, and results will need to be corrected manually, preferably by an experienced nuclear medicine physician.
Numerous advanced automatic and semi-automatic PET segmentation algorithms have been developed [43] [44] . Broadly, these can be categorized as iterative/adaptive methods, statistical modeling methods, machine by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from learning-based methods, and image filter-based methods (e.g., using gradients or texture features). Currently, it remains unclear which methods perform best and how to best assess the performance of different algorithms.
Various performance evaluation methods have been developed for testing segmentation algorithms [44] [45] . It is recommended that institutions thoroughly evaluate segmentation algorithms, including any tuning parameters, and benchmark their performance against both phantom and clinical images before clinical implementation. Even when automatic and semi-automatic tools are used, manual review of the contours is highly recommended. 
Nodal involvement
The ability of PET imaging to detect involved lymph nodes that appear benign on CT images has been demonstrated [49] . However, its improvement over CT imaging for nodal detection is dependent on the tumor site. A series of review papers have been published regarding PET for radiation treatment planning for various tumor sites, including the brain [50] , head-and-neck [51] , lung [52] , gastrointestinal cancer [53] , prostate [54] , and cervix/endometrial [55] . For some tumor sites, such as mediastinal lymph node staging for lung cancer, FDG
PET/CT appears to be superior to CT alone in sensitivity at detecting involved lymph nodes [52] . In other tumor sites, such as colorectal cancer, PET does not perform as well [56] . It remains to be seen whether or not PET/MRI scanners will improve nodal detection, particularly in some anatomical sites such as abdominal tumors.
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Tumor boosting
One appealing future application of molecular imaging in radiation therapy treatment planning is in the delineation of biological tumor subvolumes for dose escalation. This method has been termed biologicallyconformal radiation therapy, or dose painting [57] . The rationale for dose painting comes from the fact that tumors are biologically heterogeneous in composition and often show non-uniform patterns of response to radiation therapy [58] [59] . Molecular imaging may be able to identify spatial patterns of radioresistance, which can be used to guide and shape the dose distribution. Indirect evidence of this principle comes from studies that have found molecular imaging biomarkers to correlate with patient outcome following radiation therapy [60] [61] . proportional to the voxel's image intensity value [63] . Studies have demonstrated the feasibility of creating and delivering dose painting plans-both subvolume boosting and voxel-based dose painting-using existing clinical software and therapy systems [64] . Dose painting has yet to be validated as an effective treatment option, but clinical studies have begun to investigate the efficacy of dose painting. Studies have been performed in the brain using FDG [65] and FET PET [66] , in head-and-neck tumors using FDG PET [67] [68] [69] , in prostate tumors using [ 
Normal tissue sensitivity
The potential for using molecular imaging to discriminate radiosensitive tissue from radioresistant tissue in tumors may be equally valuable when applied to the surrounding normal tissue. Certain regions of an organ, particularly in the lung, appear to be more sensitive to radiation therapy than other regions of the same organ. Or some regions may be more functional than other regions, and therefore more important to spare. For example, using FDG PET imaging in the lungs, studies have found that regions of FDG uptake prior to radiation therapy are more likely to suffer radiation-induced toxicities following radiation therapy [72] . Ventilation imaging may identity lung regions that are blocked, either due to obstructive lung disease or tumor burden, which could contribute less to overall lung function than healthy functioning lung. Functional lung information can be acquired through a variety of imaging methods. For MRI, hyperpolarized gases or gadolinium aerosol can be used in combination with serial imaging to produce 4D images of lung ventilation [73] . Ventilation maps can also be derived from 4D CT imaging, where voxel Hounsfield unit values correlate with the fraction of air in the voxel volume [74] . In single-photon emission computed tomography (SPECT), Tc-labeled macro-aggregated albumin can also be used to create 3D ventilation maps [75] . The feasibility of incorporating lung ventilation maps into treatment planning for conformal avoidance has been demonstrated [76] . Although promising, the clinical benefit of using functional lung images for conformal avoidance has yet to be validated.
Overall, there are many potential uses of molecular imaging in target definition for radiation therapy. The various methods by which molecular imaging can be used for target definition and their respective degrees of complexity are outlined in Table 2 . Considering the extensive ongoing clinical research and continuous technological advances, it is likely that the methods that are presently considered to be advanced will in the near future be routine practice.
Molecular imaging for treatment response assessment
The purpose of treatment response assessment in radiation oncology depends on the time point when response is assessed (Figure 1) . Early treatment response assessment takes place during the course of radiotherapy. Its main purpose is to be an early predictor of treatment outcome and potentially allow for adaptation of the therapy in order to maximize patients' benefits. Late treatment response assessment takes place after the radiotherapy has been completed, and serves as a late predictor of treatment outcome, guiding patient care after radiotherapy. Anatomical changes visible on CT or MRI, which have been traditionally used for treatment response assessment, typically occur slowly over the course of weeks and months after the therapy [77] , whereas treatment response assessment with molecular imaging could potentially be performed much earlier.
The potential of using FDG PET SUV changes for earlier treatment response assessment was recognized by the European Organization for Research and Treatment of Cancer (EORTC) in their recommendations for the use of FDG PET/CT for treatment response assessments [78] . Later, frameworks for PET-based therapy response evaluation were drafted by the National Cancer Institute (NCI) [79] and Wahl et al., ultimately resulting in the PET Response Criteria In Solid Tumors (PERCIST) [80] . Initially, FDG PET-based therapy response assessment was only used for chemotherapy. A limitation of FDG PET-based therapy response assessment in radiation oncology is the high FDG avidity of inflamed normal tissue surrounding the tumor, which builds up late into or early after the completion of radiotherapy. In contrast to inflammatory changes in the normal tissue, the reduction of metabolic activity of the tumor is progressive during the radiotherapy. This leads to a relatively narrow window of opportunity to extract the information from molecular imaging during radiotherapy, when there are still enough viable tumor cells and before the surrounding inflammatory changes start to dominate (typically within the first 2-3 weeks).
The problem of inflammatory changes in the normal tissue during and after radiotherapy, which hinders early FDG PET/CT based assessment of radiotherapy response, is obviously FDG-specific. Other types of molecular imaging techniques, such as PET/CT with other radiotracers (e.g., FLT) or various MRI techniques by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from typically avoid this problem. However, FDG PET/CT is by far the most established molecular imaging technique, which is evident from the fact that there are no similar response assessment guidelines established yet for other types of molecular imaging techniques besides FDG PET/CT.
Prognostic/predictive role of molecular imaging in radiation therapy
High clinical availability and wide applicability are the reasons that FDG PET/CT is most commonly investigated as a prognostic and predictive imaging biomarker in radiation oncology. Relative changes in FDG SUVs are commonly investigated for being representative of clinical response, as suggested in EORTC, NCI and PERCIST guidelines for the measurement of a treatment response [78] [79] [80] . These guidelines also provide criteria for classifying patients into various response categories (complete response, partial response, stable disease, progressive disease). It should be noted that the response thresholds have not been generally validated in larger clinical trials, and therefore serve mostly as recommended guidelines for standardized reporting. In addition, FDG PET/CT-based therapy response assessment requires proper selection and control of some factors that are highly important for therapy response assessment. One of them is the timing of sequential FDG PET/CT imaging for response assessment. Due to the dynamic nature of tumor response and inflammation processes, the timing of imaging relative to the treatment schedule has a profound effect on how early treatment response can be assessed.
Some of the key studies, representing the current evidence for various tumor types, are highlighted below.
In lung cancer, clinical outcome has been correlated with the metabolic tumor response rate assessed after the end of radiotherapy. For example, overall survival at 9 months in 102 patients with non-small cell lung cancer (NSCLC) of various stages has been correlated with the metabolic tumor response rate assessed 70 days after the end of radiotherapy [81] . Furthermore, various small clinical studies have demonstrated that FDG PET/CT imaging during the course of radiotherapy can predict late metabolic response or clinical outcome in NSCLC patients [82] [83] . Timing in sequential FDG PET imaging for early response assessment is extremely important, which has been clearly demonstrated by van Baardwijk et al., who have shown that FDG PET SUV max in non-responding NSCLC patients increased in the first week of radiotherapy, then decreased in the second week of and after radiotherapy [84] . In contrast, changes in SUV max for responding patients were negligible during the radiotherapy and notably negative after the radiotherapy. FDG uptake and functional volume for both primary tumors and lymph nodes in NSCLC generally decreases during the course of radiotherapy, roughly linearly with time or dose. This suggests that FDG PET/CT images can be acquired during radiotherapy without artifacts that hamper image interpretation and quantification [85] .
In head and neck cancer, the first initiative to assess response after radiotherapy with FDG PET/CT dates back almost three decades [86] . Currently, FDG PET/CT is widely accepted for assessing response after radiotherapy or chemoradiotherapy with imaging typically performed 3 -6 months after completion of radiotherapy [87] [88] [89] . Reports on using FDG for early response assessment during radiotherapy or chemoradiotherapy are much less frequent than reports on late FDG PET/CT-based response assessment.
Generally, reports on early treatment response assessment agree that FDG PET/CT during (chemo)radiotherapy may help differentiate responders and nonresponders, but these results are not yet reliable enough to replace posttherapy FDG PET/CT evaluation [90] .
In rectal cancer, the most common therapy for early and locally advanced stage is radical surgery, which is usually preceded by preoperative radiotherapy or chemoradiotherapy. The surgical approach heavily depends on the assessment of the success of preoperative chemoradiotherapy. It has been shown that pathological response to preoperative chemoradiotherapy can be reliably evaluated by FDG PET/CT during chemoradiotherapy [91] .
Similarly, it has been shown that early FDG PET/CT performed between 1 and 2 weeks after the onset of chemoradiotherapy has high accuracy in prediction of response during preoperative chemoradiotherapy in locally advanced rectal cancer patients [92] . In addition, post-therapeutic response assessment with FDG PET has also been thoroughly studied [93] .
In esophageal cancer, late therapy response assessment with FDG PET/CT is suggested to be a significant prognostic predictor of disease-free and overall survival in locally advanced esophageal and by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from esophagogastric junction cancer during neoadjuvant treatment [94] . Early therapy response assessment with FDG PET/CT is not considered a reliable prognostic predictor in esophageal cancer [95] .
In cervical cancer, the generally accepted method for response assessment in locally advanced cervical cancer is FDG PET/CT imaging that is carried out 3 months after the completion of concurrent chemoradiotherapy, which can provide reliable long-term prognostic information [96] . Despite high predictive value of FDG PET/CT-based response assessment, relapses remain problematic. Therefore, other disease characteristics like bulky tumors (> 5 cm), extensive stage (> IIB) or pelvic and/or para-aortic lymph node metastasis could be used to direct more aggressive treatment or adjuvant chemotherapy regimens [97] . Apart from post-therapeutic response assessment, FDG PET/CT has been investigated for monitoring response during radiotherapy. Despite some promising results, future clinical trials are warranted [98] .
While some limitations of FDG PET/CT-based therapy response assessment in radiation oncology can be overcome by careful design and implementation of imaging protocol, inherent limitation due to radiation-induced inflammation makes interpretation of treatment response results difficult. In order to overcome this limitation, the focus of PET imaging is shifting to more tumor-specific characteristics (e.g., cellular proliferation, hypoxia, angiogenesis, and apoptosis). Currently, the most established of these is imaging of cellular proliferation using FLT PET, a surrogate of cellular proliferation. Uptake characteristics of FLT make it suitable for static PET imaging with reasonable uptake period and dynamic PET imaging that can be subsequently analyzed for kinetics [99] [100] . The potential for using FLT PET/CT for early therapy response assessment has been demonstrated for chemotherapy in a variety of cancers [101] [102] [103] . In the context of radiotherapy, FLT PET/CT first proved its sensitivity to ionizing radiation in preclinical tumor models [104] [105] . Following promising results of FLT PET/CT-based assessment of radiation response in preclinical models, an increasing number of studies have shown that decreased FLT uptake early (as early as 5 days/10 Gy) in the course of radiotherapy or chemoradiotherapy is a strong indicator for long-term outcome in large-animal preclinical model [106] and humans [107] [108] [109] [110] (see Figure 2) . While the data on FLT PET/CT response assessment in radiation therapy is still emerging, its potential is indisputable, and should be considered as an alternative to FDG PET/CT. One by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from alternative PET surrogate marker of cellular proliferation is 11 C-and 18 F-choline, which appears relatively sensitive for detecting recurring prostate cancer [111] . Another alternative PET surrogate marker of cellular proliferation is MET, which might be useful for late brain cancer response evaluation [112] .
Apart from cellular proliferation imaging, hypoxia is another tumor-specific characteristic that has been successfully imaged and utilized for radiotherapy response assessment in clinical studies. While tumor hypoxia is widely recognized as a negative prognostic factor in radiation oncology, hypoxic tumor subvolumes often change during the radiotherapy [113] [114] . Treatment outcome may be more correlated with the hypoxia assessment made during radiotherapy than prior to radiotherapy [115] (see Figure 2 ). Similar to PET-based radiotherapy response assessment, SPECT imaging with 99m Tc-HL91 radiotracer allows for detection of tumor hypoxia, and has significant predictive power for tumor response and patient survival [117] . SPECT imaging with 99m Tc-Hynic-rh-Annexin V Scintigraphy radiotracer also allows for evaluating apoptosis in tumors. Apoptotic SPECT imaging has shown radiation dose-dependent uptake in parotid glands within two days after the first course of chemoradiotherapy (6 to 8 Gy) in head and neck cancer patients, which was indicative of early apoptosis during radiotherapy [118] .
In addition to nuclear medicine molecular imaging techniques, MRI-based molecular imaging has long been investigated for early radiotherapy response assessment. Research has been primarily focused on DCE MRI and DW MRI. For example, increased perfusion early during the course of radiotherapy (within the first two weeks) assessed with DCE MRI has been shown to be a strong predictor of tumor regression and local control in cervical cancer treated with conventional radiotherapy [119] . Also, pre-therapy DCE MRI perfusion, permeability, or blood volume measurements have been associated with radiation treatment response in rectal cancers [120] and brain cancers [121] . Water diffusion in the tissue can be assessed with DW MRI through the ADC values. Low ADC values measured before radiotherapy have been shown to be associated with response to radiotherapy for brain lesions [122] , cervical cancer [123] and head and neck cancer patients [124] . Similarly, increases in ADC values measured during radiotherapy in brain lesions [122] , cervical cancer [123] 125] , rectal carcinomas [126] and head and neck cancer patients [124] have been shown to be associated with favorable outcome. Obstacles towards more successful use of DCE MRI or DW MRI for treatment response assessment includes the unknown optimal timing of DCE MRI imaging (which is most likely disease-dependent [127] ), and the lack of reproducibility in ADC measurements between vendors and institutions [128] .
Spatially-resolved treatment response evaluation
Solid cancers have intrinsic spatial heterogeneity in biological characteristics, which limits the efficacy of point measurements like biopsy-based molecular assays or point measures derived from PET images (e.g., SUV max ). Methods to incorporate spatial heterogeneities into treatment response assessment are an active area of research. An obvious approach to incorporate the intra-tumoral heterogeneity into treatment response would be to evaluate spatial therapeutic response. Therapeutic response could be evaluated at the voxel level as absolute change in the PET values [129] [130] or as a relative change from the baseline image [131] . Evaluation of relative changes on the voxel level is unreliable for the tumor subvolumes with very low baseline PET value, where relative changes could be high despite both baseline and post-therapy PET images having values in the range of background. Evaluation of absolute change in the PET values on the voxel level [129] [130] might be less sensitive to cases of very low baseline PET values. An evaluation of the therapeutic response on the voxel level is also highly impacted with the selection of the registration algorithm [131] .
Intra-tumoral heterogeneity could also be incorporated into treatment response assessment by the extraction of various textural features from molecular images (popularly termed radiomics). These features are subsequently used for therapy response assessment instead of or in addition to point SUV measures (i.e. SUV peak and SUV max ) or overall SUV measures (i.e. SUV mean and SUV total ). Although the use of texture analysis in molecular imaging is still in its infancy, some successful applications in radiation oncology have already been published. Various textural features that were extracted from pre-treatment FDG PET images have been correlated to treatment outcome in breast, cervix, esophageal, head and neck, and lung cancer tumors [132] .
by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from Change in textural features of FDG PET images during and after chemoradiotherapy were also significantly correlated with time-to-progression and survival in rectal cancer patients [133] .
A common technical limitation of all approaches for incorporating the intra-tumoral heterogeneity into treatment response assessment is the influence of image acquisition and reconstruction parameters on the image heterogeneity measures. Image acquisition and reconstruction intrinsically implements some smoothing and possibly other distortions in comparison to the "real" data, the degree of which depends on the imaging hardware and software, and also on the acquisition and reconstruction settings. Therefore, sequential imaging for voxelbased treatment response assessment and for extraction of imaging features would have to be performed on the same scanner with the same acquisition and reconstruction settings. Alternatively, different scanners could produce comparable results if they were carefully harmonized. However, interchangeability of textural features from different, but carefully harmonized PET/CT scanners is yet to be proved.
Adaptation
The main goal of early molecular imaging response assessment during radiation therapy is to allow for the modification of therapy to improve the clinical outcomes in cancer patients -the so-called biologically adaptive radiotherapy. The radiation treatment is adapted during therapy to match corresponding changes in tumor physiology, as derived from molecular imaging. Modeling studies have demonstrated potential for significant improvement of clinical outcome using biologically adaptive radiotherapy [134] , while the clinical evidence has yet to be provided.
Although the FDG PET/CT is the molecular imaging technique with the highest clinical acceptance and availability [68, 135] , treatment adaption based on FDG PET/CT is hampered due to the inflammatory signal after radiotherapy. The potential use of FDG PET/CT for adaptive tumor dose escalation or normal tissue sparing has been investigated in patients with NSCLC [135] and even coupled with dose painting in head and neck cancer by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from patients [68] . Both studies found significant changes in target volumes based on mid-therapy FDG PET/CT images, warranting re-planning of the treatment target mid-therapy.
In addition to FDG PET, more specific (e.g. cellular proliferation, hypoxia) imaging biomarkers could be used for radiotherapy adaption. As a rapid decrease in FLT uptake has been demonstrated as early as 5 days/10
Gy in the course of radiotherapy [107] [108] [109] [110] , early radiotherapy adaption based on FLT PET/CT imaging appears particularly attractive. Clinical utility of early radiotherapy adaption based on FLT PET/CT has yet to be demonstrated.
Normal tissue response evaluation
The main application of molecular imaging for normal tissue response evaluation is the detection of radiation-induced injuries to the normal tissue. Monitoring induction, resolution and mitigation of radiationinduced toxicity is essential in the development of clinically successful normal tissue preserving strategies.
Molecular imaging can be particularly useful to study and monitor these changes.
In lung cancer, normal tissue response assessment has been mainly focused on detection of the radiationinduced lung toxicities (RILT) and lung inflammation. The mainstay of imaging for RILT detection remains to be SPECT perfusion and ventilation for evaluating pulmonary function [75, [136] [137] [138] . In addition to SPECT perfusion and ventilation imaging, FDG PET and DCE MRI have also been investigated for RILT imaging [137] [138] . The functional relationship between post-therapy FDG uptake and radiation dose has been measured, and has been shown to correlate with the clinical symptoms of radiation pneumonitis after thoracic radiotherapy [139] .
The intensity of post-therapy FDG uptake was related to the severity of radiation pneumonitis using a simple visual scoring system [140] . Similarly, increased FDG uptake in normal lung was associated with the subsequent development of clinical RILT early during the radiotherapy [141] .
In head and neck cancer, xerostomia is the most common major normal tissue complication following radiation therapy. Decreased parotid uptake of FDG on post-radiotherapy FDG PET/CT images has been associated with the early parotid toxicity defined by post-treatment salivary output and xerostomia scores.
Interestingly, pre-treatment FDG PET/CT in conjunction with the radiation dose distribution can predict changes in parotid FDG uptake, which could potentially be exploited to guide function-sparing treatment planning [142] .
Besides the FDG PET, salivary gland function has been studied using MET PET, 99m Tc-pertechnetate SPECT and functional MRI [138] .
In esophageal cancer, research has primarily focused on assessing the myocardium for radiation-induced myocardiac damage. Focal increased uptake of FDG in the basal myocardium post-radiotherapy has been hypothesized to be related to radiation-induced myocardial damage. Therefore cardiac function and other symptoms should be followed carefully in patients with elevated FDG uptake in the myocardium [143] .
In cervical cancer, pelvic bone marrow irradiation during radiotherapy causes hematological toxicity, which can be more severe in the case of concomitant chemotherapy. Generally, bone marrow activity could be measured by several imaging modalities like CT, MRI, and PET. Imaging with FDG PET or FLT PET has been shown to help differentiate active and non-active bone marrow in cervical cancer patients who have undergone chemoradiotherapy [144] [145] .
In brain tumors, distinguishing tumor growth from radiation-induced injury is often challenging, as both are often visible on post-therapy molecular images. FDG and FLT PET imaging have shown promise in the differentiation of recurrent glioma and radiation necrosis through both quantitative and visual image assessment [146] . Similarly, FDG PET/CT and dynamic susceptibility contrast (DSC) MRI perfusion imaging have demonstrated the ability to differentiate tumor growth from radiation injury [147] . 6-[ has also been shown to effectively differentiate recurrent or progressive brain metastases from late or delayed radiation injury [148] . In addition, radiation-induced brain injury can also be assessed with various other MRI techniques [136] .
In liver cancer, liver is the most important organ at risk, so information on the spatial distribution of the liver function is highly valuable for assessing radiation-induced liver toxicity. While DCE CT is the current mainstay of liver function spatial assessment, MRI and PET/CT imaging have been studied only to a limited extent [138] .
Several specific challenges in molecular imaging of normal tissue effects remain. For example, radiation therapy is often combined with chemotherapy and molecular targeted therapies, where normal tissue toxicity can result from either modality separately or through a synergistic effect of combined therapies. Furthermore, potential inhibition of the inflammatory effects with anti-inflammatory compounds (e.g., inhibitors of NFkB and IL-1 signaling) might significantly affect radiation-induced toxicity management. Much work still needs to be done in the development of relevant molecular imaging agents to effectively probe these processes and fully explore the potential that molecular imaging offers.
Overall, there are many potential uses of molecular imaging in response assessment for radiation therapy and in the evaluation of radiation-induced injury. Various initiatives to use molecular imaging for early response assessment,treatment adaption, late response assessment, or normal tissue response evaluation in radiation oncology are outlined in Table 3 . In the context of increasing trends towards personalization of therapies , it is likely that some of the methods presented here as research initiatives will become clinical practice in the near future.
Conclusions
Molecular imaging is already strongly embedded in radiotherapy; however, the path to wide-spread and all-inclusive use in all steps of the radiation treatment process, particularly in treatment planning and treatment evaluation, is still long. The lack of solid clinical evidence is the main impediment for broader use, in addition to lack of insurance coverage for scans. Recommendations for practicing physicians are still rather scarce. Of Table 4 summarizes the NCCN's recommendations for PET/CT applications specific to radiation therapy, not including PET/CT applications in diagnosis and staging.
As the clinical evidence from multiple clinical trials and clinical practice is becoming available for different disease sites and for different applications, one can expect that this list will grow rapidly in the future. Clearly, the use of molecular imaging in radiation oncology is continuing to grow. With increasing presence, special emphasis should be put in adequate training of radiation oncology personnel to understand potential, and particularly limitations of quantitative molecular imaging applications. Furthermore, strong collaboration between radiation oncology, nuclear medicine/radiology and medical physics teams is necessary, as optimal and safe use of molecular imaging can only be assured within appropriate inter-disciplinary teams.
by on October 13, 2017. For personal use only. jnm.snmjournals.org Downloaded from Table 1 . Overview of uncertainties and quality control measures for applications of PET/CT in radiation therapy treatment planning. Similar uncertainties exist for all other molecular imaging modalities, which require specific quality control measures.
Category

Procedure Uncertainties Quality Control
Scanning protocol
Patient preparation
• Metabolism levels (FDG)
• Limit physical activity • Blood glucose levels (FDG)
• • Acquire separate low-dose CT or apply corrections • Equipment failure or electronic drift
• Frequent detector and equipment calibrations • Longer uptake period increases SUV
• Strict protocol for uptake period
Reconstruction Reconstruction
• Selection of optimal image reconstruction method/parameters
• Benchmark algorithms using phantoms (taskspecific) • Randoms, scatter, attenuation, detector sensitivity, and partial volume effect 
